Tags : Remsima

Insights+ Key Biosimilars Events of July 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a “reference […]Read More

Insights+ Key Biosimilars Events of February 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence providers are likely to adopt biosimilars “a reference product to biologics” possessing similar […]Read More

Celltrion Enters into a Contract to Manufacture Agreement for its

Shots: Celltrion has picked to manufacture its biosimilar Remsima’s drug substance at Lonza’s Singapore facility to supply it in American and European markets following its approval in the EU and the US The focus of the agreement is to diversify Celltrion’s biosimilar supply base and meet the increasing demands of the biosimilar market. In H1’19, […]Read More